Siemens' answer to pain management, a low-energy extracorporeal shock-wave therapy system called Sonocur Basic, passed FDA muster in July. The agency approved the company's new product for use in the treatment of patients with lateral epicondylitis, a
Siemens' answer to pain management, a low-energy extracorporeal shock-wave therapy system called Sonocur Basic, passed FDA muster in July. The agency approved the company's new product for use in the treatment of patients with lateral epicondylitis, a condition commonly referred to as tennis elbow. The approval is the latest evolutionary step for shock-wave therapy, which began as a treatment for kidney stones. Its failure to effectively treat biliary stones more than a decade ago caused the technology to slip from the limelight. Pain treatment promises to rejuvenate the technology, whose latest configuration is a far cry from the bulky stone-blasting machines. Sonocur Basic features an articulating head, which is placed on the painful area. The device administers a preset number of shock waves at low energy.
Also last month, the agency cleared the multimodality workstation Avia, which is being packaged with Hitachi's new PET scanner, Sceptre. The workstation with Fusion7D is designed to process and display DICOM data from any digital imaging modality.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
October 1st 2024Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.